BRPI1008855B8 - derivados de indol, seu uso como agentes anticâncer, seu processo para preparação e composição farmacêutica que os compreende - Google Patents

derivados de indol, seu uso como agentes anticâncer, seu processo para preparação e composição farmacêutica que os compreende

Info

Publication number: BRPI1008855B8
Authority: BR; Brazil
Prior art keywords: anticancer agents; preparation; indole derivatives; pharmaceutical composition; compounds
Prior art date: 2009-02-04

Application number

BRPI1008855A

Other languages

English (en)

Portuguese (pt)

Inventor

Schoentjes Bruno

Claudie Isabelle Amblard Nathalie

Descamps Sophie

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-02-04

Filing date

2010-02-03

Publication date

2021-05-25

2010-02-03 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2016-03-15 Publication of BRPI1008855A2 publication Critical patent/BRPI1008855A2/pt

2020-05-12 Publication of BRPI1008855B1 publication Critical patent/BRPI1008855B1/pt

2021-05-25 Publication of BRPI1008855B8 publication Critical patent/BRPI1008855B8/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Immunology (AREA)
Neurology (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Transplantation (AREA)
Oncology (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BRPI1008855A 2009-02-04 2010-02-03 derivados de indol, seu uso como agentes anticâncer, seu processo para preparação e composição farmacêutica que os compreende BRPI1008855B8 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP09152089		2009-02-04
EP09152089.0		2009-02-04
PCT/EP2010/051316 WO2010089327A2 (fr)	2009-02-04	2010-02-03	Dérivés d'indole en tant qu'agents anti-cancéreux

Publications (3)

Publication Number	Publication Date
BRPI1008855A2 BRPI1008855A2 (pt)	2016-03-15
BRPI1008855B1 BRPI1008855B1 (pt)	2020-05-12
BRPI1008855B8 true BRPI1008855B8 (pt)	2021-05-25

Family

ID=40738626

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1008855A BRPI1008855B8 (pt)	2009-02-04	2010-02-03	derivados de indol, seu uso como agentes anticâncer, seu processo para preparação e composição farmacêutica que os compreende

Country Status (23)

Country	Link
US (1)	US8541442B2 (fr)
EP (1)	EP2393801B1 (fr)
JP (1)	JP5612611B2 (fr)
KR (1)	KR101730407B1 (fr)
CN (1)	CN102307868B (fr)
AR (1)	AR075235A1 (fr)
AU (1)	AU2010210178B2 (fr)
BR (1)	BRPI1008855B8 (fr)
CA (1)	CA2749209C (fr)
CL (1)	CL2011001860A1 (fr)
CO (1)	CO6341625A2 (fr)
EA (1)	EA021883B1 (fr)
ES (1)	ES2639752T3 (fr)
IL (1)	IL214427A (fr)
MX (1)	MX2011008195A (fr)
MY (1)	MY152018A (fr)
NO (1)	NO20111199A1 (fr)
NZ (1)	NZ594186A (fr)
SG (1)	SG173495A1 (fr)
TW (1)	TWI476189B (fr)
UA (1)	UA107455C2 (fr)
WO (1)	WO2010089327A2 (fr)
ZA (1)	ZA201105695B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2841517B2 (ja)	1989-08-11	1998-12-24	株式会社ツムラ	入浴剤
JP2872763B2 (ja)	1990-06-28	1999-03-24	紀伊産業株式会社	携帯用肛門洗浄器
WO2013063492A1 (fr)	2011-10-28	2013-05-02	Board Of Regents, The University Of Texas System	Nouvelles compositions et procédés pour traiter le cancer
US9719970B2 (en)	2012-11-30	2017-08-01	Waters Technologies Corporation	Methods and apparatus for the analysis of vitamin D metabolites
CN113480530A (zh)	2016-12-26	2021-10-08	阿里根公司	芳香烃受体调节剂
CN106632303A (zh) *	2017-01-09	2017-05-10	湖南华腾制药有限公司	一种6‑噻唑基吲哚衍生物的制备方法
CN111587249A (zh)	2017-11-20	2020-08-25	阿里根公司	吲哚化合物及其用途
CN108659003B (zh) *	2018-04-14	2021-01-26	上海朝晖药业有限公司	一种治疗口腔溃疡的化合物的制备方法
EP3907218A4 (fr) *	2019-01-04	2022-09-21	Jiangsu Hengrui Medicine Co., Ltd.	Dérivé de 6-oxo-1,6-dihydropyridazine, son procédé de préparation et son utilisation médicale
BR112021014178A2 (pt) *	2019-02-20	2021-09-21	Jiangsu Hengrui Medicine Co., Ltd.	Derivado de pró-fármaco de 6-oxo-1,6-diidropiridazina, método de preparação para o mesmo e aplicação do mesmo na medicina
CA3137027A1 (fr)	2019-04-15	2020-10-22	Ariagen, Inc.	Composes d'indole chiraux et leur utilisation
WO2024102758A2 (fr) *	2022-11-08	2024-05-16	The General Hospital Corporation	Séries n-(n-aminoalkyl)phénanthridiunium de fluorophores sensibles au chlorure et leurs procédés d'utilisation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR901228A (fr)	1943-01-16	1945-07-20	Deutsche Edelstahlwerke Ag	Système d'aimant à entrefer annulaire
AUPO863197A0 (en)	1997-08-18	1997-09-11	Fujisawa Pharmaceutical Co., Ltd.	Novel derivatives
US6309492B1 (en)	1998-09-16	2001-10-30	Marc A. Seidner	Polymer fill coating for laminate or composite wood products and method of making same
UA71587C2 (uk)	1998-11-10	2004-12-15	Шерінг Акцієнгезелльшафт	Аміди антранілової кислоти та їхнє застосування як лікарських засобів
EA003326B1 (ru)	1998-12-02	2003-04-24	Пфайзер Продактс Инк.	Способ лечения рака
AU1734401A (en)	1999-12-09	2001-06-18	Mitsubishi Pharma Corporation	Carboxyamido derivatives
SG126006A1 (en)	2000-09-15	2006-10-30	Anormed Inc	Chemokine receptor binding heterocyclic compounds
KR100894189B1 (ko)	2001-03-29	2009-04-22	일라이 릴리 앤드 캄파니	5-ｈｔ6 수용체의 길항제로서의 ｎ-(2-아릴에틸)벤질아민
WO2003040402A2 (fr)	2001-11-09	2003-05-15	The Regents Of The University Of California	Mimetisme de l'helice alpha par une classe de molecules organiques
NZ532463A (en)	2001-11-13	2007-02-23	Dimensional Pharm Inc	Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
WO2003051359A1 (fr)	2001-12-18	2003-06-26	F.Hoffmann-La Roche Ag	Cis-2,4,5- triphenyl-imidazolines et leurs utilisations dans le traitement des tumeurs
GB0215650D0 (en)	2002-07-05	2002-08-14	Cyclacel Ltd	Bisarylsufonamide compounds
KR101331786B1 (ko) *	2004-09-22	2013-11-21	얀센 파마슈티카 엔.브이.	Ｍｄｍ2 및 ｐ53간의 상호작용 저해제
CA2644643C (fr) *	2006-03-22	2015-05-19	Janssen Pharmaceutica N.V.	Inhibiteurs de l'interaction entre mdm2 et p53
CA2644649C (fr)	2006-03-22	2014-06-17	Janssen Pharmaceutica N.V.	Derives d'alkylamine cyclique en tant qu'inhibiteurs de l'interaction entre mdm2 et p53
US20100129933A1 (en) *	2007-04-26	2010-05-27	Forschungszentrum Karlsruhe Gmbh	Method for detecting the binding between mdm2 and the proteasome
AR067813A1 (es)	2007-08-06	2009-10-21	Janssen Pharmaceutica Nv	Fenilendiaminas sustituidas como inhibidores de l ainteraccion entre mdm2 y p53
JO2704B1 (en) *	2007-09-21	2013-03-03	جانسين فارماسوتيكا ان في	Interference inhibition factors between MD2 and B53
JP5438008B2 (ja)	2007-09-21	2014-03-12	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	ＭＤＭ２とｐ５３の間の相互作用の阻害剤

2010
- 2010-02-03 MX MX2011008195A patent/MX2011008195A/es active IP Right Grant
- 2010-02-03 MY MYPI2011003583 patent/MY152018A/en unknown
- 2010-02-03 TW TW099103103A patent/TWI476189B/zh not_active IP Right Cessation
- 2010-02-03 CN CN201080007001.9A patent/CN102307868B/zh not_active Expired - Fee Related
- 2010-02-03 KR KR1020117020348A patent/KR101730407B1/ko not_active Expired - Fee Related
- 2010-02-03 SG SG2011055431A patent/SG173495A1/en unknown
- 2010-02-03 US US13/147,707 patent/US8541442B2/en not_active Expired - Fee Related
- 2010-02-03 EP EP10702310.3A patent/EP2393801B1/fr active Active
- 2010-02-03 WO PCT/EP2010/051316 patent/WO2010089327A2/fr not_active Ceased
- 2010-02-03 JP JP2011548674A patent/JP5612611B2/ja not_active Expired - Fee Related
- 2010-02-03 AU AU2010210178A patent/AU2010210178B2/en not_active Ceased
- 2010-02-03 EA EA201170997A patent/EA021883B1/ru not_active IP Right Cessation
- 2010-02-03 ES ES10702310.3T patent/ES2639752T3/es active Active
- 2010-02-03 BR BRPI1008855A patent/BRPI1008855B8/pt not_active IP Right Cessation
- 2010-02-03 AR ARP100100298A patent/AR075235A1/es unknown
- 2010-02-03 CA CA2749209A patent/CA2749209C/fr active Active
- 2010-02-03 NZ NZ594186A patent/NZ594186A/xx not_active IP Right Cessation
- 2010-03-02 UA UAA201109449A patent/UA107455C2/uk unknown
2011
- 2011-07-12 CO CO11087033A patent/CO6341625A2/es not_active Application Discontinuation
- 2011-08-02 ZA ZA2011/05695A patent/ZA201105695B/en unknown
- 2011-08-02 CL CL2011001860A patent/CL2011001860A1/es unknown
- 2011-08-03 IL IL214427A patent/IL214427A/en active IP Right Grant
- 2011-09-02 NO NO20111199A patent/NO20111199A1/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
BRPI1008855B1 (pt)	2020-05-12
TWI476189B (zh)	2015-03-11
MX2011008195A (es)	2011-09-06
IL214427A (en)	2016-02-29
CA2749209A1 (fr)	2010-08-12
BRPI1008855A2 (pt)	2016-03-15
US20110294846A1 (en)	2011-12-01
NZ594186A (en)	2012-12-21
UA107455C2 (uk)	2015-01-12
ZA201105695B (en)	2014-01-29
MY152018A (en)	2014-08-15
CA2749209C (fr)	2017-01-10
AR075235A1 (es)	2011-03-16
CN102307868B (zh)	2016-06-22
TW201038552A (en)	2010-11-01
ES2639752T3 (es)	2017-10-30
NO20111199A1 (no)	2011-11-04
AU2010210178A1 (en)	2011-07-28
AU2010210178B2 (en)	2014-06-05
KR101730407B1 (ko)	2017-04-26
WO2010089327A3 (fr)	2010-10-21
EA201170997A1 (ru)	2012-01-30
CL2011001860A1 (es)	2012-07-20
US8541442B2 (en)	2013-09-24
JP5612611B2 (ja)	2014-10-22
CO6341625A2 (es)	2011-11-21
CN102307868A (zh)	2012-01-04
WO2010089327A2 (fr)	2010-08-12
KR20110116195A (ko)	2011-10-25
IL214427A0 (en)	2011-09-27
EP2393801B1 (fr)	2017-07-12
SG173495A1 (en)	2011-09-29
EA021883B1 (ru)	2015-09-30
JP2012516872A (ja)	2012-07-26
EP2393801A2 (fr)	2011-12-14

Publication	Publication Date	Title
BRPI1008855B8 (pt)	2021-05-25	derivados de indol, seu uso como agentes anticâncer, seu processo para preparação e composição farmacêutica que os compreende
CO6470845A2 (es)	2012-06-29	Derivados de pirimidina novedosos y su uso en el tratamiento del cancer y enfermedades adicionales
BRPI0910388A2 (pt)	2019-06-11	agentes terapêutico antivirais.
ECSP12012318A (es)	2013-02-28	Inhibidores de pirazolil quinazolina cinasa
CO6771439A2 (es)	2013-10-15	Inhibidores de benzodioxano de la producción de leucotrieno
UY31183A1 (es)	2009-01-30	Derivados de pirazinona y procesos para su preparación
CO6351783A2 (es)	2011-12-20	Derivados de indazoles sustituidos con fenilo o piridinilo
SV2011003855A (es)	2011-05-16	Heteroarilos sustituidos
BR112016000909A8 (pt)	2020-01-07	derivados piperidinil indólicos, seus usos, e combinação e composição farmacêuticas
BR112014000792A2 (pt)	2017-10-31	compostos de piperidinila para uso como inibidores da tanquirase
ECSP11011183A (es)	2011-10-31	Compuestos orgánicos
ECSP11011184A (es)	2011-10-31	Compuestos orgánicos
UY32611A (es)	2010-12-31	Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750
GT201200334A (es)	2014-12-22	Morfolinopirimidinas y su uso en terapia
BR112015026023A2 (pt)	2017-07-25	derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
BRPI0916286B8 (pt)	2021-05-25	amidofenóxi-indazóis úteis como inibidores de c-met, seus usos, e composição farmacêutica
UY34955A (es)	2014-01-31	4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
UY32426A (es)	2010-09-30	Derivados bicilicos para uso en el tratamiento de enfermedades relacionadas al receptor de androgeno
UY31905A (es)	2010-01-29	Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
BRPI1014802B8 (pt)	2021-05-25	profármacos de triptolida.
BR112012009310A2 (pt)	2016-06-07	composto, e, composição farmacêutica
UY32744A (es)	2011-01-31	Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
CO6321288A2 (es)	2011-09-20	Sales de compuestos inhibidores de vih
BR112012009670A2 (pt)	2016-05-17	compostos de cumarina como moduladores de receptor com utilidade terapêutica
DOP2010000155A (es)	2010-07-15	Derivados de pirazol como inhibidores de 5-lo

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-03-26	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-04-24	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2019-08-20	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2020-03-03	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-05-12	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/05/2020, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/02/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2023-11-28	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 14A ANUIDADE.
2024-03-19	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2760 DE 28-11-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.